<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03088553</url>
  </required_header>
  <id_info>
    <org_study_id>35RC16_9773</org_study_id>
    <nct_id>NCT03088553</nct_id>
  </id_info>
  <brief_title>Observational Study Comparing the Efficacy of Ganciclovir as a Function of Blood Exposure to the Drug During a Curative or Preemptive Treatment</brief_title>
  <acronym>GANEX</acronym>
  <official_title>Etude Observationnelle Comparant l'efficacité du GANciclovir en Fonction de l'EXposition Sanguine au médicament</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rennes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rennes University Hospital</source>
  <oversight_info>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to better define the target range of ganciclovir trough concentrations by
      investigating the relationship between ganciclovir concentration and the time to undetectable
      CMV-DNA load, in preemptive and curative treatments by (val)ganciclovir.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of the study is to determine whether higher concentrations of
      ganciclovir can reduce the time of negation of the CMV-DNA load.

      Secondary objectives are to determine the concentration-toxicity relationship of ganciclovir
      and the relationship between concentrations of ganciclovir and apparition of CMV gene
      mutations responsible of drug resistance.

      Each week, trough concentrations of ganciclovir are measured, associated with control of
      CMV-DNA load and all biological analysis currently necessary for the monitoring of the
      infection.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 22, 2017</start_date>
  <completion_date type="Anticipated">April 2020</completion_date>
  <primary_completion_date type="Anticipated">April 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Time to CMV viral load negativity as a function of the median of trough concentrations of ganciclovir</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>Duration of patient follow-up for the CMV infection</description>
  </primary_outcome>
  <enrollment type="Anticipated">138</enrollment>
  <condition>Solid Organ Transplantation</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Therapeutic Drug Monitoring</intervention_name>
    <description>Trough concentration of ganciclovir and viral load measurement at each follow-up visit.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Solid organ transplanted patients with CMV reactivation or CMV disease.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  more than 18 years-old

          -  Solid organ transplanted patients needing a treatment by oral or intravenous
             (val)ganciclovir

          -  Non-opposition to participate in the study.

        Exclusion Criteria:

          -  pregnancy

          -  opposition to participate in the study

          -  incapable person
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Kristell COAT</last_name>
    <phone>2 99 28 91 91</phone>
    <phone_ext>+33</phone_ext>
    <email>kristell.coat@chu-rennes.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Direction de la recherche</last_name>
    <phone>2 99 28 25 55</phone>
    <phone_ext>+33</phone_ext>
    <email>DRC@chu-rennes.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Rennes</name>
      <address>
        <city>Rennes</city>
        <zip>35000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clémence MD VERDIER</last_name>
      <phone>299284361</phone>
      <phone_ext>+33</phone_ext>
      <email>clemence.verdier@chu-rennes.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 10, 2017</study_first_submitted>
  <study_first_submitted_qc>March 16, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 23, 2017</study_first_posted>
  <last_update_submitted>May 15, 2017</last_update_submitted>
  <last_update_submitted_qc>May 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 16, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ganciclovir</keyword>
  <keyword>trough concentrations</keyword>
  <keyword>CMV viral load</keyword>
  <keyword>safety</keyword>
  <keyword>Solid organ transplantation (heart, kidney or liver)</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ganciclovir</mesh_term>
    <mesh_term>Ganciclovir triphosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

